Skip to main content
. Author manuscript; available in PMC: 2024 Jul 19.
Published in final edited form as: J Clin Trials. 2024 May 13;14(4):563.

Figure 2:

Figure 2:

The PLUMM Study design. Note: R-randomization; MMFBSA-treatment arm of MMF dosed at 600 mg/m2 body surface area about 12 hours apart; MMFPK-treatment arm of MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0–12h) of MPA ≥ 60–70 mg*h/L, CRR-complete renal response; PRR-partial renal response; NR-non-responder; CYC-cyclophosphamide.